EUVIMEDEUVIMED entdecken
Crossref

Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation

Jing Liu iD, Xiao-Su Zhao, Ying-Jun Chang, Ya-Zhen Qin iD, Qian Jiang iD, Hao Jiang, Xiao-Hui Zhang iD, Lan-Ping Xu iD, Yu Wang iD, Meng Lv, Kai-Yan Liu iD, Xiao-Jun Huang iD und 1 weitere

British Journal of Haematology · 2025-05 · 206 (5) · 1418-1429

DOI: 10.1111/bjh.20036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 13.03.2025. Verfasst von Jing Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Science, Technology & Innovation Project of Xiongan New Area, Beijing Nova Program, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the kinetics of KMT2A ‐r during chemotherapy and its impact on allogeneic haematopoietic stem cell transplantation (allo‐HSCT) outcomes. KMT2A‐r was assessed post‐induction (MRD1), after the first (MRD2) and second (MRD3) consolidations and pre‐transplant (MRD4) in 52 patients with acute myeloid leukaemia (AML). KMT2A ‐r significantly decreased from diagnosis to MRD2 ( p < 0.001 for diagnosis vs. MRD1; p = 0.019 for MRD1 vs. MRD2). The incidence of KMT2A‐r negativity (57.5%) peaked at MRD2. KMT2A ‐r status at each time point significantly affected post‐transplant outcomes. Cluster analysis identified four KMT2A ‐r kinetic profiles: persistently negative (−/−), turned negative at transplant (+/−), turned positive at transplant (−/+) and persistently positive (+/+). The (−/−) group had the best outcomes, with a cumulative incidence of relapse (CIR) of 13.0%, overall survival (OS) of 82.0% and leukaemia‐free survival (LFS) of 81.7%. The (+/+) group had the worst prognosis, with a CIR of 58.8%, OS of 29.4% and LFS of 23.5%. KMT2A dynamics were an independent risk factor for CIR (Hazard ratio [HR] = 11.070, 95%CI 2.395–51.165, p = 0.002), LFS (HR = 9.316, 95%CI 2.656–32.668, p < 0.001) and OS (HR = 7.172, 95%CI 1.999–25.730, p = 0.003). In conclusion, KMT2A ‐r status after chemotherapy and its kinetics are significant HSCT prognostic indicators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseHumansFemaleMaleMiddle AgedAdultRecurrenceAdolescentTransplantation, HomologousYoung AdultPrognosisAged

Stichwörter der Autor:innen

KMT2Aacute myeloid leukaemiaallogeneic haematopoietic stem cell transplantationmeasurABLe residual diseasemultiparameter flow cytometry

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking Univer…
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.

ORCID-Profile: Jing Liu, Ya-Zhen Qin, Qian Jiang, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Kai-Yan Liu, Xiao-Jun Huang, Xiang-Yu Zhao

Förderung

  • Science, Technology & Innovation Project of Xiongan New Area
  • Beijing Nova Program
  • the National Natural Science Foundation of China
  • the National Key Research and Development Program of China
  • Beijing Outstanding Young Scientists Project
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Liu, J., Zhao, X. S., Chang, Y. J., Qin, Y. Z., Jiang, Q., Jiang, H., Zhang, X. H., Xu, L. P., Wang, Y., Lv, M., Liu, K. Y., Huang, X. J., & Zhao, X. Y. (2025). Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 206(5), 1418-1429. https://doi.org/10.1111/bjh.20036

Vancouver

Liu J, Zhao XS, Chang YJ, Qin YZ, Jiang Q, Jiang H, et al. Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2025;206(5):1418-1429. doi:10.1111/bjh.20036

BibTeX
@article{Liu2025,
  author = {Liu, Jing and Zhao, Xiao-Su and Chang, Ying-Jun and Qin, Ya-Zhen and Jiang, Qian and Jiang, Hao and Zhang, Xiao-Hui and Xu, Lan-Ping and Wang, Yu and Lv, Meng and Liu, Kai-Yan and Huang, Xiao-Jun and Zhao, Xiang-Yu},
  title = {Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {5},
  pages = {1418--1429},
  doi = {10.1111/bjh.20036}
}
Kostenlos starten →